Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Uwe Platzbecker, Elena Crisa, Sophie Salazar, Thomas Cluzeau, Antonella Poloni, Raquel De Paz Arias, Thibault Comont, Sebastian Grosicki, Aristoteles Giagounidis, Matteo Della Porta, Pellegrino Musto, Mar Tormo, Dominic Brauer, Ana Alfonso-Pierola, Stefania Paolini, Sophie Park, Annelies Weyn, Lionel Ades, Valeria Santini

Blood (2025) 146 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2025-5649

Published: 2025

Journal Articles

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Luca Lanino, Matteo Zampini, Ivan Civettini, Daniele Ramazzotti, Alessia Campagna, Elena Riva, Denise Ventura, Nicole Pinocchio, Pasquale Niscola, Marco Gabriele Raddi, Angela Consagra, Federica Pilo, Antonella Poloni, Mariarita Sciumè, Andrea Patriarca, Stefania Paolini, Carlo Finelli, Andrea Castelli, Pellegrino Musto, Anna Calvisi, Grazia Sanpaolo, Monia Marchetti, Elisa Diral, Germana Beltrami, Carmen Fava, Claudio Fozza, Chiara Frairia, Carmine Selleri, Daniela Barraco, Domenico Pastore, Rosanna Ciancia, Elena Crisa, Enrico Balleari, Susanna Gallo, Vincenzo Pavone, Esther Natalie Oliva, Giulia Maggioni, Ferdinando Frigeri, Gabriele Todisco, Antonio Russo, Alessandro Buizza, Ivan Ferrari, Giulia Figini, Alessandra Crespi, Elisa Calvetti, Chiara Milanesi, Nicla Manes, Francesco Pesce, Saverio D'Amico, Gianluca Asti, Elisabetta Sauta, Guido Sanguinetti, Gastone Castellani, Marilena Bicchieri, Ilaria Naldi, Francesca Ficara, Valeria Santini, Marta Ubezio, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3842.

https://doi.org/10.1182/blood-2025-3842

Published: 2025

Journal Articles

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Blood (2025) 146 (Supplement 1): 2685.

https://doi.org/10.1182/blood-2025-2685

Published: 2025

Journal Articles

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Anna Calvisi, Rosangela Filiberti, Daniela Barraco, Massimo Bernardi, Isabella Capodanno, Andrea Castelli, Rosanna Ciancia, Carmen Fava, Carla Fili, Chiara Frairia, Francesco Frattini, Piero Galieni, Pasquale Niscola, Stefania Paolini, Andrea Patriarca, Anna Maria Pelizzari, Grazia Sanpaolo, Carmine Selleri, Francesco Alesiani, Gianni Binotto, Costanza Bosi, Catello Califano, Barbara Castagnari, Elena Crisa, Monica Crugnola, Marco De Gobbi, Matteo Della Porta, Nicola Di Renzo, Dario Ferrero, Carlo Finelli, Carla Foli, Claudio Fozza, Maurizio Frezzato, Ferdinando Frigeri, Gianluca Guaragna, Monia Marchetti, Daniele G. Mattei, Mara Memoli, Paola Minetto, Alfredo Molteni, Pellegrino Musto, Esther Natalie Oliva, Giuseppe Alberto Palumbo, Fabrizio Pane, Giuseppe Pietrantuono, Federica Pilo, Antonella Poloni, Giulia Rivoli, Mariarita Sciumè, Rodolfo Tassara, Mauro Turrini, Letizia Zannoni, Ilaria Naldi, Enrico Balleari, Valeria Santini, Francesco Onida

Blood (2025) 146 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2025-2080

Published: 2025

Journal Articles

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Blood (2025) 146 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2025-5631

Published: 2025

Journal Articles

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Blood (2024) 144 (Supplement 1): 4532.

https://doi.org/10.1182/blood-2024-211476

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Blood (2024) 144 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2024-207175

Published: 2024

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3906–3907.

https://doi.org/10.1182/blood-2022-170415

Published: 2022

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

Journal Articles

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135972

Published: 2020

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Blood (2019) 134 (Supplement_1): 839.

https://doi.org/10.1182/blood-2019-127488

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A “Campus CML” Study

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only